Abstract B176: Results of a phase I study of PLX8394, a next-generation BRAF inhibitor, in refractory solid tumors
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b176
Abstract: Background: First-generation BRAF inhibitors (BRAFi) such as vemurafenib and dabrafenib demonstrated high response rates and prolonged survival in some BRAFV600-mutated cancers; however, most patients ultimately develop resistance. Furthermore, treatment-emergent skin and other epithelial malignancies present… read more here.
Keywords: generation; phase study; braf; plx8394 ... See more keywords
Abstract 5523: Inhibition of FASN postpones development of resistance to PLX8394 in colorectal cancer
Sign Up to like & getrecommendations! Published in 2025 at "Cancer Research"
DOI: 10.1158/1538-7445.am2025-5523
Abstract: Mutations in proto-oncogene B-Raf (BRAF) occur in about 10% of colorectal cancer (CRC) patients and BRAFV600E is the most common type. This subset of CRC is associated with a reduced response to chemotherapy and poor… read more here.
Keywords: resistance; fasn; crc; resistance plx8394 ... See more keywords